1 / 8

LH / Q3012R Molecular Biology, Immunology, & Genetics of Coagulation Factors

LH / Q3012R Molecular Biology, Immunology, & Genetics of Coagulation Factors. Jay Lozier, M.D., Ph.D. Principal Investigator Report to the Blood Products Advisory Committee, September 29, 2005 on February 25, 2005 LH Site Visit. LH Regulatory Issues: Inhibitors to Factors VIII/IX.

sagittarius
Télécharger la présentation

LH / Q3012R Molecular Biology, Immunology, & Genetics of Coagulation Factors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LH / Q3012R Molecular Biology, Immunology, & Genetics of Coagulation Factors Jay Lozier, M.D., Ph.D. Principal Investigator Report to the Blood Products Advisory Committee, September 29, 2005 on February 25, 2005 LH Site Visit

  2. LH Regulatory Issues:Inhibitors to Factors VIII/IX Public Health Impact/Mission Relevance • Antibodies to coagulation factors prevent the use of therapeutic products in ~20% of patients with hemophilia. • Understanding factors that control whether patients make antibodies to therapeutic products is important for evaluation of their immunogenicity. LH / Q3012R Lozier, PI

  3. Research Questions/Problems • Are there genetic factors in patients that influence inhibitors? • Are there animal models in which to study the problem? • How can we leverage FDA resources to study this problem using outside resources and collaborators? LH / Q3012R Lozier, PI

  4. Mouse Animal Models Using genetically well-characterized inbred mouse strains we have shown: • MHC genes, T-cell receptors, and zinc-a-2-glycoprotein 1 genes influence the antibody response to human factor VIII • MHC genes and to a lesser extent, cytokine genes (IL10, Interferon-g) control the antibody response to human factor IX. Lozier, et al., Blood 2005;105:1029-1035. LH / Q3012R Lozier, PI

  5. Hemophilia A Dog Model The Chapel Hill hemophilia A dogs are an ideal model in which to study mechanisms for inhibitor antibodies: • The Chapel Hill hemophilia A dogs have a gene inversion identical to that in ~40% of humans with severe hemophilia A. • The bleeding phenotype is identical to human hemophilia A. • The dogs can & do make inhibitors when treated with dog factor VIII. Lozier et al, PNAS 2002;99:12991-12996 LH / Q3012R Lozier, PI

  6. Future Directions: Pharmacogenomics I We will test the hypothesis that genes identified in the mouse have similar influence on inhibitor antibodies in hemophilia dogs, and the hypothesis that differences in the normal factor VIII protein can influence development of inhibitors in hemophilia A. LH / Q3012R Lozier, PI

  7. Future Directions: Pharmacogenomics II We will test the hypothesis that candidate genes identified in the mouse have similar influence on inhibitor antibodies in humans with hemophilia A. LH / Q3012R Lozier, PI

  8. Personnel/Collaborators • Jay Lozier, M.D., Ph.D., Principal Investigator • Nahid Tayebi, Ph.D., Staff Fellow • Laura Wood, B.S., Biologist • Pei Zhang, M.D., Collaborator (DH/LPD) • Timothy Nichols, M.D., Collaborator (UNC) • James Goedert, M.D., Collaborator (NCI) • Marjory Brooks, D.V.M., Collaborator (Cornell) LH / Q3012R Lozier, PI

More Related